Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01805180 · ClinicalTrials.gov registry record · NA
Evaluation of the Spectra Optia PMN Cell Collection Procedure
A NA study, sponsored by Terumo BCT.
- Completed
- Registry status
- NA
- Development phase
- 42
- Enrollment target
NCT01805180: Completed NA study, sponsored by Terumo BCT.
NCT01805180 is a NA study that has completed, run by Terumo BCT. The registered enrollment target is 42 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01805180, a NA study, has completed, sponsored by Terumo BCT.
- COMPLETED
- Registry status
- NA
- Development phase
- 42 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the procedures for the collection PMN cells on Terumo BCT's Spectra Optia® and COBE® Spectra Apheresis Systems.
Primary Outcome
The primary endpoint is the granulocyte/PMN cell collection efficiency (CE) associated with the Granulocyte (PMN) Collection Procedures on the Spectra Optia and COBE Spectra Apheresis Systems. CE is a measurement of device performance calculated using donor and blood product blood counts collected immediately before and after the PMN collection procedure.
Interventions
- DEVICE Granulocyte/Polymorphonuclear Cell Collection (COBE Spectra System)
- DEVICE Granulocyte/Polymorphonuclear Cell Collection (Spectra Optia System)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2013-02 |
| Est. Completion | 2013-07 |
| Phase | NA |
What the finished NCT01805180 record still lists
NCT01805180 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Granulocyte/Polymorphonuclear Cell Collection (COBE Spectra System) is the first listed.
NCT01805180 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01805180 about?
NCT01805180 is a clinical study titled "Evaluation of the Spectra Optia PMN Cell Collection Procedure". The purpose of this study is to compare the procedures for the collection PMN cells on Terumo BCT's Spectra Optia® and COBE® Spectra Apheresis Systems.
What is the current status of trial NCT01805180?
This trial is currently completed. It is a NA study. The enrollment target is 42 participants. The study started on 2013-02. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01805180?
The interventions under investigation include: Granulocyte/Polymorphonuclear Cell Collection (COBE Spectra System) (DEVICE), Granulocyte/Polymorphonuclear Cell Collection (Spectra Optia System) (DEVICE).
Who is sponsoring clinical trial NCT01805180?
This trial is sponsored by Terumo BCT, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01805180's enrollment target sits among peer trials
42 1436th of 2000 higher than 555 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia